Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach